As a company committed to our patients, our strategy is mainly focused on investing in innovation and development of new products that improve the health of these people. With this goal in mind, we have started 2022 with many new features, from our entry into the OTC market as a result of the acquisition of the company Fisiopharma to our collaboration with the Sincrolab start-up, in which we have invested in order to form part of the innovative treatment for ADHD they have developed.
Sincrolab has the mission to give comprehensive access to the latest advances in neuroscience, through cutting-edge technologies. As a result, it has managed to develop a technology based on Artificial Intelligence for the treatment of ADHD.
As pioneers in the introduction of the first pharmaceutical product for the treatment of ADHD, this collaboration represents a great step forwards that will foster the creation and development of increasingly accurate treatments for patients, using the latest technologies in the market.
After over 50 years of experience, we have earned the respect of the medical community, thanks to our ability to understand what health professionals need to better develop their work and offer patients quality healthcare.
What does this new prescription treatment consist of?
It is a training platform aimed towards the recovery and development of cognitive abilities. It is a personalised stimulation system, in which patients use a mobile application to perform tasks designed by neuroscientists who specialise in the field. The purpose of these interventions is to reorganise the brain connectivity of patients who suffer some kind of neurocognitive disorder.
Why Sincrolab?
The association with Sincrolab is a firm commitment to Digital Therapeutics, a tool that enables us to advance in the future of medicine and neurocognitive rehabilitation treatments.
Furthermore, like us, the patient is at the centre of our strategy, which means that our goal is to offer products and services that improve the quality of life of each patient.
We are convinced that this collaboration will be highly successful for both companies and all our patients.
